by Brenda Baletti, Ph.D. A “substantial proportion” of infants immunized against the RSV virus with the monoclonal antibody shot nirsevimab — marketed by Sanofi and AstraZeneca as Beyfortus — developed…
October 9, 2025
by Brenda Baletti, Ph.D. A “substantial proportion” of infants immunized against the RSV virus with the monoclonal antibody shot nirsevimab — marketed by Sanofi and AstraZeneca as Beyfortus — developed…